1. Home
  2. WFF vs APVO Comparison

WFF vs APVO Comparison

Compare WFF & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WF Holding Limited Ordinary Shares

WFF

WF Holding Limited Ordinary Shares

N/A

Current Price

$2.05

Market Cap

10.2M

ML Signal

N/A

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WFF
APVO
Founded
1984
2016
Country
Malaysia
United States
Employees
142
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
WFF
APVO
Price
$2.05
$4.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.8K
28.4K
Earning Date
05-24-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.50
52 Week High
$29.22
$13.11

Technical Indicators

Market Signals
Indicator
WFF
APVO
Relative Strength Index (RSI) 55.87 44.76
Support Level $0.38 $4.29
Resistance Level $2.08 $5.66
Average True Range (ATR) 0.18 0.35
MACD -0.02 0.01
Stochastic Oscillator 57.38 33.48

Price Performance

Historical Comparison
WFF
APVO

About WFF WF Holding Limited Ordinary Shares

WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings, and other custom-made FRP products. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance. Geographically, the company generates the majority of its revenue from Australia.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: